OverviewChartNewsTraderScreen

BVT Aktienanleihe BAYN 31.12.2024/  DE000VM287D7  /

Frankfurt Zert./VONT
11/09/2024  20:01:29 Chg.-1.220 Bid20:48:59 Ask20:48:59 Underlying Strike price Expiration date Option type
62.340EUR -1.92% 62.400
Bid Size: 50,000		 62.810
Ask Size: 50,000		 BAYER AG NA O.N. 46.00 EUR 31/12/2024 Call
TeleTrader 16/08 Bayer jumps 10% after Roundup court win
GlobeNewswire 02/08 Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting A...
GlobeNewswire 11/07 AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational...
GlobeNewswire 25/06 AskBio Initiates Recruitment to its Phase 2 Parkinson’s Disease Trial
GlobeNewswire 30/05 Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
GlobeNewswire 30/05 BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’...
GlobeNewswire 29/05 Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach
GlobeNewswire 28/05 Pairwise and Bayer Expand CRISPR Leafy Greens Market through Licensing Agreement
TeleTrader 14/05 Bayer's sales in Q1 at €13.7 billion, down 4.3%
GlobeNewswire 02/05 AskBio Announces Nine Presentations at American Society of Gene and Cell Therapy 27th Annual Meeting...
GlobeNewswire 18/04 AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in conge...
GlobeNewswire 16/04 AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’...
GlobeNewswire 11/04 Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from...
GlobeNewswire 09/04 AskBio Names Mansuo Shannon Chief Scientific Officer
GlobeNewswire 25/03 BlueRock Therapeutics and Foundation Fighting Blindness announce collaboration to expand the Uni-Rar...
GlobeNewswire 14/03 Bayer and Aignostics to collaborate on next generation precision oncology
GlobeNewswire 06/03 BlueRock Therapeutics phase I clinical trial for Parkinson’s disease continues to show positive tren...
TeleTrader 05/03 Bayer's Q4 sales at €11.9 billion
GlobeNewswire 04/03 BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
TeleTrader 04/03 Earnings preview: Bayer, Broadcom among those in calendar
GlobeNewswire 15/02 2Blades Delivers on Project with Bayer Crop Science to Combat Asian Soybean Rust
GlobeNewswire 13/02 Corporate Alignment with Climate Goals Under Scrutiny: LyondellBasell & Bayer demonstrate good pract...
GlobeNewswire 13/02 First patient randomized in AskBio Phase II gene therapy trial for congestive heart failure
TeleTrader 29/01 Bayer down over 5% after latest $2.25B Roundup ruling
TeleTrader 17/01 Bayer to cut jobs amid 'difficult situation'